US · A · MEDICAL - DIAGNOSTICS & RESEARCH
Agilent Technologies, Inc. (A) intrinsic value and stock valuation
$170.38as of 2026-11-21 · Mkt cap 39.85B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Agilent Technologies, Inc. DCF and intrinsic value
InvestorsCraft values A with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from A’s statements →
Agilent Technologies, Inc. Graham Number
Graham Number: $49.68d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Cardinal Health, Inc. (CAH) $272.81
- Edwards Lifesciences Corporation (EW) $101.85
- Becton, Dickinson and Company (BDX) $212.78
- Haleon plc (HLN) $9.07
- IQVIA Holdings Inc. (IQV) $245.82
- Alcon Inc. (ALC) $74.31
- ResMed Inc. (RMD) $235.63
- Mettler-Toledo International Inc. (MTD) $1,666.88
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.95B | $6.51B | $6.83B | $6.85B | $6.32B |
| Operating income | $1.48B | $1.49B | $1.35B | $1.62B | $1.35B |
| Net income | $1.3B | $1.29B | $1.24B | $1.25B | $1.21B |
| EPSd | $4.59M | $4.43M | $4.19M | $4.18M | $3.94M |
| Operating cash flow | $1.56B | $1.75B | $1.77B | $1.31B | $1.49B |
| Capital expenditure | -$-407M | -$-378M | -$-298M | -$-291M | -$-189M |
| Free cash flow | $1.15B | $1.37B | $1.47B | $1.02B | $1.3B |
| Total assets | $12.7B | $11.8B | $10.8B | $10.5B | $10.7B |
| Total debt | $3.35B | $3.57B | $2.74B | $2.77B | $2.73B |
| Net debt | $1.57B | $2.25B | $1.15B | $1.72B | $1.25B |
| Total equity | $6.74B | $5.9B | $5.85B | $5.31B | $5.39B |
| Cash and short-term investments | $1.79B | $1.33B | $1.59B | $1.05B | $1.58B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $6.95B | $6.51B | $6.83B | $6.85B | $6.32B |
| Cost of revenue | $3.31B | $2.98B | $3.37B | $3.13B | $2.91B |
| Gross profit | $3.64B | $3.54B | $3.47B | $3.72B | $3.41B |
| Research and development expenses | $455M | $479M | $481M | $467M | $441M |
| Selling, general and administrative expenses | $1.71B | $1.52B | $1.63B | $1.64B | $1.62B |
| Other expenses | $0.00 | $50M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $2.16B | $2.05B | $2.12B | $2.1B | $2.06B |
| Cost and expenses | $5.47B | $5.02B | $5.48B | $5.23B | $4.97B |
| Interest income | $62M | $80M | $51M | $9M | $2M |
| Interest expense | $112M | $96M | $95M | $84M | $81M |
| Depreciation and amortization | $288M | $257M | $271M | $317M | $321M |
| Ebitda | $1.84B | $1.87B | $1.7B | $1.91B | $1.76B |
| Operating income | $1.48B | $1.49B | $1.35B | $1.62B | $1.35B |
| Total other income/expenses, net | -$-44M | $33M | -$-11M | -$-114M | $13M |
| Income before tax | $1.44B | $1.52B | $1.34B | $1.5B | $1.36B |
| Income tax expense | $132M | $232M | $99M | $250M | $150M |
| Net income | $1.3B | $1.29B | $1.24B | $1.25B | $1.21B |
| Weighted average shares outstanding | $283M | $290M | $294M | $299M | $304M |
| Weighted average diluted shares outstanding | $284M | $291M | $296M | $300M | $307M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.79B | $1.33B | $1.59B | $1.05B | $1.58B |
| Net receivables | $1.49B | $1.32B | $1.29B | $1.41B | $1.17B |
| Inventory | $1.03B | $991M | $1.03B | $1.04B | $830M |
| Total current assets | $4.59B | $3.96B | $4.19B | $3.78B | $3.8B |
| Property, plant and equipment, net | $2.02B | $1.96B | $1.42B | $1.1B | $945M |
| Goodwill and intangible assets | $4.92B | $5.02B | $4.44B | $4.77B | $4.96B |
| Long-term investments | $133M | $175M | $164M | $195M | $185M |
| Total non-current assets | $8.13B | $7.89B | $6.58B | $6.75B | $6.91B |
| Total assets | $12.7B | $11.8B | $10.8B | $10.5B | $10.7B |
| Accounts payable | $570M | $540M | $418M | $580M | $446M |
| Short-term debt | $304M | $87M | $0.00 | $36M | $0.00 |
| Deferred revenue | $624M | $544M | $505M | $461M | $441M |
| Total current liabilities | $2.35B | $1.9B | $1.6B | $1.86B | $1.71B |
| Long-term debt | $3.05B | $3.49B | $2.74B | $2.73B | $2.73B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $3.64B | $4.05B | $3.32B | $3.37B | $3.61B |
| Capital lease obligations | $0.00 | $184M | $0.00 | $0.00 | $0.00 |
| Total liabilities | $5.99B | $5.95B | $4.92B | $5.23B | $5.32B |
| Common stock | $3M | $3M | $3M | $3M | $3M |
| Retained earnings | $1.39B | $750M | $782M | $324M | $348M |
| Accumulated other comprehensive income (loss) | -$-226M | -$-305M | -$-327M | -$-347M | -$-282M |
| Total equity | $6.74B | $5.9B | $5.85B | $5.31B | $5.39B |
| Total investments | $133M | $175M | $164M | $195M | $276M |
| Total debt | $3.35B | $3.57B | $2.74B | $2.77B | $2.73B |
| Net debt | $1.57B | $2.25B | $1.15B | $1.72B | $1.25B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $434M | $1.29B | $1.24B | $1.25B | $1.21B |
| Depreciation and amortization | $288M | $257M | $271M | $317M | $321M |
| Stock-based compensation | $128M | $129M | $111M | $125M | $110M |
| Change in working capital | -$-58M | $83M | -$-116M | -$-478M | -$-102M |
| Accounts receivable | -$-149M | $7M | $132M | -$-321M | -$-128M |
| Inventory | $45M | $34M | -$-33M | -$-248M | -$-136M |
| Accounts payable | $16M | $103M | -$-171M | $121M | $64M |
| Net cash provided by operating activities | $1.56B | $1.75B | $1.77B | $1.31B | $1.49B |
| Investments in property, plant and equipment | -$-207M | -$-378M | -$-298M | -$-291M | -$-189M |
| Acquisitions, net | $4M | -$-862M | -$-1M | -$-52M | -$-546M |
| Net cash used for investing activities | -$-394M | -$-1.26B | -$-310M | -$-338M | -$-749M |
| Common stock issued | $72M | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-425M | -$-1.15B | -$-575M | -$-1.14B | -$-788M |
| Dividends paid | -$-282M | -$-274M | -$-265M | -$-250M | -$-236M |
| Net cash used for financing activities | -$-715M | -$-752M | -$-930M | -$-1.37B | -$-696M |
| Net change in cash | $459M | -$-261M | $537M | -$-434M | $43M |
| Cash at end of period | $1.79B | $1.33B | $1.59B | $1.06B | $1.49B |
| Operating cash flow | $1.56B | $1.75B | $1.77B | $1.31B | $1.49B |
| Capital expenditure | -$-407M | -$-378M | -$-298M | -$-291M | -$-189M |
| Free cash flow | $1.15B | $1.37B | $1.47B | $1.02B | $1.3B |
Line items
Line items
Line items
About Agilent Technologies, Inc.
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- CEO
- Padraig McDonnell
- Employees
- 18.1K
- Beta
- 1.25
Included in
Explore
Frequently asked questions
What is the intrinsic value of Agilent Technologies, Inc. (A)?
Agilent Technologies, Inc. (A) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is A undervalued?
A trades at a price of $170.38 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.